Alnylam Pharmaceuticals, Inc.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
FY2009
Asset Breakdown FY2013
Total Assets: $420.5M
Liabilities Breakdown FY2013
Total Liabilities: $150.2M
Asset Breakdown
Total Assets: $420.5M
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $53.2M | 12.6% |
| Accounts Receivable | $4.2M | 1.0% |
| Inventory | $0 | 0.0% |
| Property, Plant & Equipment | $16.4M | 3.9% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $346.7M | 82.4% |
Liabilities Breakdown
Total Liabilities: $150.2M
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $5.9M | 3.9% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $144.3M | 96.1% |